CN110090197A - A kind of film-formable anesthesia face mask cream - Google Patents
A kind of film-formable anesthesia face mask cream Download PDFInfo
- Publication number
- CN110090197A CN110090197A CN201910322402.6A CN201910322402A CN110090197A CN 110090197 A CN110090197 A CN 110090197A CN 201910322402 A CN201910322402 A CN 201910322402A CN 110090197 A CN110090197 A CN 110090197A
- Authority
- CN
- China
- Prior art keywords
- film
- face mask
- parts
- formable
- anesthesia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000006071 cream Substances 0.000 title claims abstract description 47
- 206010002091 Anaesthesia Diseases 0.000 title claims abstract description 42
- 230000037005 anaesthesia Effects 0.000 title claims abstract description 41
- 230000003444 anaesthetic effect Effects 0.000 claims abstract description 26
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 19
- 239000011159 matrix material Substances 0.000 claims abstract description 8
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims abstract description 6
- 229940072056 alginate Drugs 0.000 claims abstract description 6
- 235000010443 alginic acid Nutrition 0.000 claims abstract description 6
- 229920000615 alginic acid Polymers 0.000 claims abstract description 6
- 229920001661 Chitosan Polymers 0.000 claims abstract description 4
- -1 anaesthetic Substances 0.000 claims abstract 3
- 239000004909 Moisturizer Substances 0.000 claims description 11
- 230000001333 moisturizer Effects 0.000 claims description 11
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 10
- 239000003963 antioxidant agent Substances 0.000 claims description 10
- 230000003078 antioxidant effect Effects 0.000 claims description 10
- 235000006708 antioxidants Nutrition 0.000 claims description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 9
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 5
- 229930003268 Vitamin C Natural products 0.000 claims description 5
- 235000019154 vitamin C Nutrition 0.000 claims description 5
- 239000011718 vitamin C Substances 0.000 claims description 5
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 4
- 230000008901 benefit Effects 0.000 claims description 4
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims description 4
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 4
- 229910019142 PO4 Inorganic materials 0.000 claims description 3
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 3
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 claims description 3
- 235000011180 diphosphates Nutrition 0.000 claims description 3
- 229920000609 methyl cellulose Polymers 0.000 claims description 3
- 239000001923 methylcellulose Substances 0.000 claims description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 3
- 239000010452 phosphate Substances 0.000 claims description 3
- 108010024636 Glutathione Proteins 0.000 claims description 2
- 159000000007 calcium salts Chemical group 0.000 claims description 2
- 229960003180 glutathione Drugs 0.000 claims description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims 3
- 239000001913 cellulose Substances 0.000 claims 1
- 229920002678 cellulose Polymers 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 8
- 238000004140 cleaning Methods 0.000 abstract description 6
- 239000003814 drug Substances 0.000 abstract description 5
- 229940079593 drug Drugs 0.000 abstract description 4
- 230000000699 topical effect Effects 0.000 abstract description 3
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 12
- 229960004194 lidocaine Drugs 0.000 description 12
- 230000036407 pain Effects 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 6
- 239000002674 ointment Substances 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 210000002615 epidermis Anatomy 0.000 description 4
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 4
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 4
- 229940071676 hydroxypropylcellulose Drugs 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 230000002335 preservative effect Effects 0.000 description 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000003285 pharmacodynamic effect Effects 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000003020 moisturizing effect Effects 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 210000003497 sciatic nerve Anatomy 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical group CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 241000269420 Bufonidae Species 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 235000006754 Taraxacum officinale Nutrition 0.000 description 1
- 240000001949 Taraxacum officinale Species 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000036982 action potential Effects 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 238000001949 anaesthesia Methods 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000002316 cosmetic surgery Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7015—Drug-containing film-forming compositions, e.g. spray-on
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Anesthesiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a kind of film-formable anesthesia face mask creams, including matrix, anaesthetic, film forming agent, retarder；The film forming agent is at least one of alginate, chitosan and its derivative.Face mask cream of the present invention uses the forming technique of filmogen, it can be according to user's needs, it is applied on designated treatment region, quickly site of anesthesia can needed to form a film, and it can be with quick separating, facilitate clinical workers operation application, save the process of the topical application of drug, guarantee for a person given by a shopkeeper's wet film, removal, cleaning, removes numb cream without using sterile gauze or other instruments.
Description
Technical field
The present invention relates to a kind of anesthesia cream, especially a kind of film-formable anesthesia face mask cream.
Background technique
Current clinically used surface anesthesia dosage form, mostly lidocaine or compound lidocaine ointment, for part
Or full-face anesthesia uses, and clinical workers is to reduce moisture evaporation, and increase the absorption of anesthetic composition, after often smearing, paving
Upper preservative film guarantees certain therapeutic effect, after surface anesthesia, apply it is preoperative need to tear preservative film, and with sterile gauze or its
His aseptic apparatus, removal are attached to the numb cream of local Shi Shuqu, while being also required to, Fang Kejin clean with sterile use water or alcohol washes
Row surgical procedure.
However, the removal fiber crops cream, cleaning operation process is relatively long, about 5-10 minutes, in addition lidocaine or and similar
Derivative, the anesthetic effect time is shorter, and often after operation for clearance, anaesthetic effect just fades away, and can not be up to
Anaesthetic effect.Moreover, if allergic reaction occurs, patient lures in removal using the lidocaine of paste or its same analog derivative
Because during, often also because removal process is very complicated, and surface fiber crops cream can not be removed in time.
In addition, quick-anaesthesia may be implemented, but the technology is with certain traumatic while shallow although injection lidocaine
The injection of epidermis often very pain, can not receive, although applying anesthesia ointment by epidermis, user's susceptibility can be improved,
In the topical application of drug or cleaning process, operation is relatively inconvenient, but is also received reluctantly by clinical workers.
Summary of the invention
Based on this, a kind of film-formable fiber crops are provided it is an object of the invention to overcome above-mentioned the deficiencies in the prior art place
Liquor-saturated face mask cream.
To achieve the above object, the technical solution used in the present invention are as follows: a kind of film-formable anesthesia face mask cream, including base
Matter, anaesthetic, film forming agent, retarder；The film forming agent is at least one of alginate, chitosan and its derivative.
Anesthesia cream of the present invention is mixed using filmogen, retarder, anaesthetic, can according to user's needs,
It is applied on designated treatment region, quickly site of anesthesia can needed to form a film, and can be with quick separating, without using sterile gauze
Or other instruments remove numb cream.
Preferably, the retarder is calcium salt.Herein described retarder can be very good in conjunction with the filmogen,
The filmogen is set quickly site of anesthesia to be needed to form a film, and can be with quick separating.The two share with it is rapid-action, continue when
Between it is short, anesthesia efficiency is high, controllability is strong in art, art finishes the advantages that revival is fast.
It is highly preferred that the retarder be anhydrous sulfate, dihydric phosphate, hydrophosphate, in pyrophosphate at least
It is a kind of.Above-mentioned retarder can make the filmogen quickly need site of anesthesia preferably in conjunction with the filmogen
Film forming, and can be with quick separating.
Preferably, the parts by weight of the anaesthetic are 10~25 parts, and the parts by weight of the film forming agent are 5~15 parts, described slow
The parts by weight of solidifying agent are 5~15 parts.
Inventor passes through a large amount of exploration discoveries, and the content ratio of above-mentioned each ingredient is more advantageous to fast filming, easily peelable,
Facilitating clinical workers operation application, saves the process of the topical application of drug, guarantee for a person given by a shopkeeper's wet film, removal, cleaning, film technique can be removed quickly,
Art can be applied after simple cleaning.
It is highly preferred that the parts by weight of the film forming agent are 5~10 parts, the parts by weight of the retarder are 10~15 parts.?
Within the scope of the content ratio of above-mentioned film forming agent and retarder, the anesthesia face mask cream can form a film faster, and easily peelable.
It is highly preferred that the weight ratio of the film forming agent and the retarder are as follows: film forming agent: retarder=2:3.Inventor's warp
A large amount of exploration discoveries are crossed, when the weight ratio of film forming agent and retarder is 2:3, film-formation result and peeling effect are best, user
Susceptibility be preferably also.
Preferably, the anaesthetic is at least one of lidocaine and its derivative.
Preferably, the matrix contains at least one of hydroxy propyl cellulose, methylcellulose.
Preferably, the film-formable anesthesia face mask cream also includes moisturizer or/and promotor.Anaesthetic of the invention
Cream, it is interior to be moisturized containing moisturizer and promotor with moistening skin epidermis, promote anesthetic composition to enter, clinical position
Person no longer needs to carry out moisturizing operation with preservative film, reduces preoperative cumbersome work.
It is highly preferred that the parts by weight of the moisturizer are 10~20 parts.
It is highly preferred that the moisturizer is at least one of polyvinyl alcohol, polyethylene glycol, propylene glycol, glycerol.
Preferably, the film-formable anesthesia face mask cream, also includes antioxidant, and the antioxidant is vitamin C, paddy Guang
At least one of sweet peptide.Antioxidant is primarily to further protect skin.Antioxidant and promotor in the present invention contain
Amount, those skilled in the art can select according to the actual situation.
In addition, the preparation method of herein described anesthesia cream, those skilled in the art can prepare according to conventional methods.
Compared with the existing technology, the invention has the benefit that
Anesthesia cream of the present invention is mixed using filmogen, retarder, anaesthetic, using the molding skill of filmogen
Art can be applied on designated treatment region according to user's needs, quickly site of anesthesia can needed to form a film, and can be fast
Speed separation removes numb cream without using sterile gauze or other instruments.
Meanwhile anaesthetic cream of the invention, it is interior to be moisturized containing moisturizer and promotor with moistening skin epidermis,
Anesthetic composition is promoted to enter, clinical workers no longer needs to carry out moisturizing operation with preservative film, reduces preoperative cumbersome work.
Specific embodiment
To better illustrate the object, technical solutions and advantages of the present invention, below in conjunction with specific embodiment to the present invention
It is described further.
Embodiment 1
The present invention, which can form a film, anaesthetizes a kind of embodiment of face mask cream, and anesthesia face mask cream described in the present embodiment includes following weight
The ingredient of part:
100 parts of matrix (containing hydroxy propyl cellulose), 10 parts of anaesthetic (lidocaine), 5 parts of film forming agent (alginate),
5 parts of retarder (anhydrous sulfate), 10 parts of moisturizer (polyvinyl alcohol), 3 parts of antioxidant (vitamin C).
Paste is conventionally made in mentioned component, as described can form a film anaesthetizes face mask cream.
Embodiment 2
The present invention, which can form a film, anaesthetizes a kind of embodiment of face mask cream, and anesthesia face mask cream described in the present embodiment includes following weight
The ingredient of part:
100 parts of matrix (containing methylcellulose), 25 parts of anaesthetic (derived from lidocaine object), film forming agent (chitosan) 15
Part, 15 parts of retarder (dihydric phosphate), 20 parts of moisturizer (polyethylene glycol), 5 parts of promotor, 5 parts of antioxidant (glutathione).
Paste is conventionally made in mentioned component, as of the present invention form a film anaesthetizes face mask cream.
Embodiment 3
The present invention, which can form a film, anaesthetizes a kind of embodiment of face mask cream, and anesthesia face mask cream described in the present embodiment includes following weight
The ingredient of part:
100 parts of matrix (containing hydroxy propyl cellulose), 25 parts of anaesthetic (lidocaine), film forming agent (alginate) 10
Part, 15 parts of retarder (hydrophosphate), 10 parts of moisturizer (polyvinyl alcohol), 3 parts of antioxidant (vitamin C).
Paste is conventionally made in mentioned component, as of the present invention form a film anaesthetizes face mask cream.
Embodiment 4
The present invention, which can form a film, anaesthetizes a kind of embodiment of face mask cream, and anesthesia face mask cream described in the present embodiment includes following weight
The ingredient of part:
100 parts of matrix (containing hydroxy propyl cellulose), 10 parts of anaesthetic (lidocaine), 5 parts of film forming agent (alginate),
10 parts of retarder (pyrophosphate), 20 parts of moisturizer (glycerol), 5 parts of promotor, 5 parts of antioxidant (vitamin C).
Paste is conventionally made in mentioned component, as of the present invention form a film anaesthetizes face mask cream.
Embodiment 5
Summarized according to clinical observation curative effect: from the point of view of clinical 100 results used, surgery anesthesia effective percentage is up to 98.2%
(local skin is painless, performs the operation without pain, postoperative experience sense is preferable), inefficiency be only 1.8% (local skin paralysis, without pain,
There is slight feeling of pain in the course of surgery).It is as follows to name three specific clinical application cases:
Case 1, patient, female, 26 years old, the micro- lift face of face.This ointment is dipped in small cotton swab, is embrocated repeatedly at about 10 points of face
Clock, row cosmetic surgery have been handled and have been easy to film stripping.Patient, which is reflected, has no other feelings, without pain at operation.
Case 2, patient, female, 45 years old, wound, face's scald smeared facial affected part using this ointment 10 minutes repeatedly, row
Operation.Patient, which is reflected, has no other feelings, without pain at operation.
Case 3, patient, male, 32 years old, wound, face scratched and needs to suture.After primary haemostasis, cleaning wound, this ointment is used
Affected part is smeared repeatedly 8 minutes, row stitching processing has been handled and has been easy to film stripping.Patient has no pain, also bad anti-without other
It answers.
Embodiment 6
The verifying of anaesthetic effect specific experiment
5 groups of experiments, respectively experimental group 1~4 and control group are set, and experimental group 1~4 is to use the embodiment of the present application respectively
Anesthesia face mask cream in 1~4, control group are to use existing compound lidocaine ointment common on the market.Prepare 75 toads,
It is divided into 5 groups, every group 15.
With reference to " cooperative learning and ridge frog reflecting experimental " (Wang Xiaojun cooperative learning and ridge frog reflecting experimental
Inside and outside the classroom [J]: teacher's version, 2011 (9): 72-72.) and " the pharmacodynamics preliminary experiment of toad crow surface anaesthetic is studied " (
Gorgeous, Dai Jiayin, Zhang Min wait the pharmacodynamics preliminary experiment of toad crow surface anaesthetic to study the healthy digest in the China and foreign countries [J], and 2011,08
(7): 50-52. qualified ridge toad) is preselected, then referring to " shadow of the lidocaine to frog sciatic nerve-trunk action potential conduction of velocity
Ring " carry out sciatic nerve separation.
Anesthesia cream in experimental group 1~4 and control group is uniformly applied to the left lower extremity sciatic nerve isolated, is then joined
Examining " the pharmacodynamics preliminary experiment of toad crow surface anaesthetic is studied ", (Zhang Yan, Dai Jiayin, Zhang Min wait the medicine of toad crow surface anaesthetic
Effect learns the healthy digest in the China and foreign countries preliminary experiment research [J], 2011,08 (7): 50-52.), it detects the drug effect time and drug is made
Use the duration.Experimental results are as shown in table 1.
Table 1
As it can be seen from table 1 compared with the control group, the application can form a film face mask cream with anesthesia onset fast, anesthesia maintenance
The feature that time is long and medical separation is fast, moreover, the effect of experimental group 3,4 will be substantially better than experimental group 1,2, and experimental group 3
Effect it is best.
Finally, it should be noted that the above embodiments are merely illustrative of the technical solutions of the present invention rather than protects to the present invention
The limitation of range is protected, although the invention is described in detail with reference to the preferred embodiments, those skilled in the art should
Understand, it can be with modification or equivalent replacement of the technical solution of the present invention are made, without departing from the essence of technical solution of the present invention
And range.
Claims (10)
1. a kind of film-formable anesthesia face mask cream, which is characterized in that including matrix, anaesthetic, film forming agent, retarder；The film forming
Agent is at least one of alginate, chitosan and its derivative.
2. film-formable anesthesia face mask cream as described in claim 1, which is characterized in that the retarder is calcium salt.
3. film-formable anesthesia face mask cream as claimed in claim 2, which is characterized in that the retarder be anhydrous sulfate,
At least one of dihydric phosphate, hydrophosphate, pyrophosphate.
4. film-formable anesthesia face mask cream as described in claim 1, which is characterized in that the parts by weight of the anaesthetic are 10~25
Part, the parts by weight of the film forming agent are 5~15 parts, and the parts by weight of the retarder are 5~15 parts.
5. film-formable anesthesia face mask cream as claimed in claim 4, which is characterized in that the parts by weight of the film forming agent are 5~
10 parts, the parts by weight of the retarder are 10~15 parts.
6. film-formable anesthesia face mask cream as claimed in any one of claims 1 to 5, which is characterized in that the anaesthetic is benefit
At least one of cacaine and its derivative.
7. film-formable anesthesia face mask cream as claimed in any one of claims 1 to 5, which is characterized in that the matrix contains hydroxyl
At least one of base propyl cellulose, methylcellulose.
8. film-formable anesthesia face mask cream as claimed in any one of claims 1 to 5, which is characterized in that also comprising moisturizer or/
And promotor.
9. film-formable anesthesia face mask cream as claimed in claim 8, which is characterized in that the moisturizer is polyvinyl alcohol, gathers
At least one of ethylene glycol, glycerol.
10. film-formable anesthesia face mask cream as claimed in any one of claims 1 to 5, which is characterized in that it also include antioxidant,
The antioxidant is at least one of vitamin C, glutathione.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910322402.6A CN110090197A (en) | 2019-04-19 | 2019-04-19 | A kind of film-formable anesthesia face mask cream |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910322402.6A CN110090197A (en) | 2019-04-19 | 2019-04-19 | A kind of film-formable anesthesia face mask cream |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110090197A true CN110090197A (en) | 2019-08-06 |
Family
ID=67445444
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910322402.6A Pending CN110090197A (en) | 2019-04-19 | 2019-04-19 | A kind of film-formable anesthesia face mask cream |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110090197A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1093897A (en) * | 1993-04-22 | 1994-10-26 | 孟丽君 | The preparation method of surface anesthesia film |
| CA2268535A1 (en) * | 1996-10-14 | 1998-04-23 | Kowa Company, Ltd. | Local anesthetic for external use |
| US20160022603A1 (en) * | 2013-03-15 | 2016-01-28 | Vapogenix, Inc. | Novel analgesic compositions |
-
2019
- 2019-04-19 CN CN201910322402.6A patent/CN110090197A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1093897A (en) * | 1993-04-22 | 1994-10-26 | 孟丽君 | The preparation method of surface anesthesia film |
| CA2268535A1 (en) * | 1996-10-14 | 1998-04-23 | Kowa Company, Ltd. | Local anesthetic for external use |
| US20160022603A1 (en) * | 2013-03-15 | 2016-01-28 | Vapogenix, Inc. | Novel analgesic compositions |
Non-Patent Citations (1)
| Title |
|---|
| 孟胜男，等: "《药剂学》", 31 January 2016, 中国医药科技出版社 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN114558110B (en) | Mussel mucin product and application thereof in inhibiting skin inflammation | |
| CN115300508A (en) | Topical formulations comprising montelukast in combination with mussel adhesive protein | |
| WO2013000382A1 (en) | Fatty acid composition and plant extract and pharmaceutical preparation and application thereof | |
| EP3656388A1 (en) | Composition, system and method for treating skin | |
| JP2020529392A (en) | Compositions for the prevention or treatment of scars | |
| BRODY | Topical treatment of recurrent herpes simplex and post‐herpetic erythema multiforme with low concentrations of zinc sulphate solution | |
| CN108904876A (en) | A kind of liquid wound dressing and preparation method thereof | |
| CN105687230A (en) | Nevus-removing cream and preparation method thereof | |
| WO1993025209A1 (en) | Compositions for the treatment and prophylaxis of inflammations and dermatoses induced by viruses and process for the preparation thereof | |
| CN110090197A (en) | A kind of film-formable anesthesia face mask cream | |
| WO2018072731A1 (en) | Wound healing composition | |
| KR101820519B1 (en) | Use of sulglycotide for promoting skin-wound-healing, and composition for external application comprising the same | |
| CN106880765A (en) | A kind of structure of wound animal model and the method for promoting wound healing | |
| WO2021191811A1 (en) | A novel wound gel composition | |
| KR20120140450A (en) | Composition for promoting the differentiation of human mesenchymal stem cell | |
| JP6506482B1 (en) | Pharmaceutical composition for use in scalp or skin modification, wound healing, or hair modification | |
| KR20120009183A (en) | Composition for promoting the differentiation of human mesenchymal stem cell | |
| Fox | Photographic Atlas of the Diseases of the Skin | |
| Spigel | Opportunistic cutaneous myiasis | |
| CN108852927A (en) | A kind of pox-dispelling function skin care compositions and its application containing growth factor | |
| CN203042644U (en) | Aloe wound paste | |
| EP3393464A1 (en) | Composition for the treatment of keratosis | |
| CN107281631A (en) | It is a kind of to cover leucoderma or the method for hickie | |
| Winston et al. | Structure of Skin Epidermis is derived from ectoderm and is approximately 75–150 µm in thickness over most of the body [1]. Epidermis is constantly renewed at a variable rate, but complete renewal occurs over 36-75 days. The epidermis has five layers: stratum corneum, stratum lucidum, stratum granulosum, stratum spinosum, and stratum | |
| TWI634896B (en) | Uses of osmanthus fragrans extracts for manufacturing a composition for enhancing hair growth and a composition for wound healing |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20201223 Address after: 510000 704, General Hospital of Guangzhou Military Region, 111 Liuhua Road, Yuexiu District, Guangzhou City, Guangdong Province Applicant after: Yuan Kaihua Address before: 510030 No.106 Fengze East Road, Nansha District, Guangzhou City, Guangdong Province (self compiled Building 1) x1301-i3280 Applicant before: GUANGZHOU RUIYI BIOTECHNOLOGY Co.,Ltd. |
|
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20190806 |